– A 75-year-old man who was vaccinated against Corona 19 died in Israel. Israeli authorities have said there is no link between vaccine and death, but concerns about side effects could spread.
The Israeli Ministry of Health said on the 28th (local time) that a 75-year-old man from Betzian died of a heart attack within hours after receiving the Corona 19 vaccine developed by US pharmaceutical company Pfizer and German Bioentech. According to the Jerusalem Post, the man died two hours after vaccination. This happened after I confirmed that there were no side effects of the vaccine and left the hospital.
The Israeli Ministry of Health said initial investigations did not reveal a link between death and vaccines.
According to the Ministry of Health, the man suffered from diseases such as heart disease and cancer. Concerns may increase over the situation in which patients with underlying diseases or those with weakened immunity are getting the vaccine.
Israel has started large-scale COVID-19 vaccinations for medical personnel and the elderly since the 20th, and about 500,000 people have been vaccinated so far.
According to the global statistics agency Our World Day (OWID), Israel is the number one vaccination rate per population, with about 4.37 vaccinations completed per 100 population. Bahrain, the United Kingdom, the United States, and Canada follow.
Earlier, Pfizer said in a data submitted to the US Food and Drug Administration (FDA) that six out of 43,000 participants died in the vaccine clinical process. Two of them were actually vaccinated and four were in the control group who received the sham vaccine. From this, Pfizer concluded that there was no causal relationship between vaccine and death.
The U.S., where the spread of COVID-19 has not declined even after vaccination has started, is accelerating to supply a third vaccine. According to the Wall Street Journal (WSJ) that day, NovaVax is conducting large-scale phase 3 clinical trials of COVID-19 vaccine candidates in the United States and Mexico. It is targeted at 30,000 people over the age of 18. NovaVax is the fifth time in the U.S. to start a phase 3 clinical trial for the COVID-19 vaccine, following Pfizer Biontech, Modena, Johnson & Johnson, and AstraZeneca.
Anthony Pouch, director of the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health, told the Associated Press that “at least 85% of the population needs an amount to inoculate.” “I need a sheep.” The U.S. government has funded $1.6 billion for NovaVax vaccine research. In return, it promised to provide the US government with a dose of 100 million doses.
The spread of mutant viruses found in the UK and South Africa has not stopped. According to Kyodo News on the 29th, the Ministry of Health, Labor and Welfare of Japan confirmed seven new mutant virus infections the day before. One of them was a woman in her 30s who was infected with the South African mutant virus.
According to Develt, medical staff at Hannover Medical School in Germany concluded that the virus from the UK began to spread in Europe last month. Amid the spread of the mutant virus in various countries, India also reported a case of mutant virus infection from the UK, Reuters reported.
[김덕식 기자]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
–
